Imatinib is employed for Philadelphia chromosome‐positive chronic granulocytic leukemia treatment, sorafenib has shown efficacy in advanced renal cell carcinoma treatment, and ongoing trials involve tivozanib targeting VEGFR for related diseases.28 This evidence concerns the gene KDR and hereditary clear cell renal cell carcinoma.